Shares of GRI Bio, Inc. (GRI) more than tripled on Tuesday morning after it reported interim safety results from its ongoing Phase 2a study evaluating GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis.
GRI is currently trading at $9.51, up $6.31 or 197.19%, on the Nasdaq. The stock opened its trading at $9.37 after closing Monday at $3.20. The stock has traded between $3.05 and $165.75 in the past 52-week period.
GRI-0621, is the company's small molecule RAR-ß? dual agonist that inhibits the activity of human Type 1 Invariant NKT cells. In preliminary clinical trials to date and previous clinical trials with the oral formulation, GRI-0621 has been shown to improve fibrosis in multiple disease models and improve liver function tests and other markers of inflammation and injury in patients.
The pre-planned interim analysis for 2-week safety results from the ongoing Phase 2a biomarker study demonstrated GRI-0621 to be safe and well-tolerated in the first 12 patients evaluated per protocol.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.